SCHEMBL24968328

SCHEMBL24968328

CCOC(=O)Cc1cc(C(F)(F)F)c(=O)[nH]n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 7/20 0.41
GLA P06280 1/20 0.41
TIPARP Q7Z3E1 1/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
POLB P06746 3/20 0.38
CYP1A2 P05177 1/20 0.38
THRB P10828 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
FPR1 P21462 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860084 0.81 KDM4E (0.36) ALDH1A1SMN1; SMN2KDM4EGLATIPARP
SCHEMBL24968908 0.80 TIPARP (0.43) TIPARPTHRBLMNA
SCHEMBL30851298 0.79 TIPARP (0.42) TIPARP
SCHEMBL30859849 0.78 TIPARP (0.40) ALDH1A1KDM4EGLATIPARPHPGD
SCHEMBL8720083 0.76 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL7860349 0.75 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL30859999 0.75 TIPARP (0.44) ALDH1A1KDM4EGLATIPARPHPGD
SCHEMBL28575636 0.74 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2KDM4ECA12CA1
SCHEMBL23930792 0.73 ALPL (0.46) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL30860080 0.72 TIPARP (0.39) SMN1; SMN2KDM4ETIPARPCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 CN disclosed
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2024-10-24 US disclosed
EP-4378938-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-06-05 EP disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
CN-117642393-A Novel PARP7 inhibitor and application thereof 上海齐鲁制药研究中心有限公司 2024-03-01 CN disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 ALDH1A1 1213/4885SMN1; SMN2 889/4885KDM4E 3606/4885
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF PARP6, PARP4, PARP3 ALDH1A1 549/4885SMN1; SMN2 3311/4885KDM4E 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.